Fintel reports that on May 28, 2025, Leerink Partners downgraded their outlook for Rocket Pharmaceuticals (NasdaqGM:RCKT) ...

Fintel reports that on May 28, 2025, Leerink Partners downgraded their outlook for Boundless Bio (NasdaqGS:BOLD) from ...

Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Fulcrum Therapeutics (FULC) stock gains as Leerink Partners upgrades the stock, citing a favorable risk-reward setup ahead of a key trial readout. Read more here.

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the ...

Halozyme Therapeutics (HALO) stock remains under pressure as Morgan Stanley downgrades the company on Medicare price negotiation concerns. Read more here.

On Tuesday, Leerink Partners adjusted its stance on Johnson & Johnson (NYSE:JNJ) stock, downgrading it from Outperform to Market Perform. The firm also lowered its price target to $153 from the ...